Search clinical trials for: ACU193

Total 27 results

Acumen Pharmaceuticals

Recruiting

A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD) (ALTITUDE-AD)

Alzheimer Disease

United States, France, Italy, Germany, Spain, Canada, Poland, United Kingdom
Acumen Pharmaceuticals
National Institute on Aging (NIA)

Completed

A Study to Evaluate the Safety, Tolerability, and Blood Levels of ACU193 in Participants With MCI or Mild AD (INTERCEPT-AD)

Alzheimer Disease

United States
Azora Therapeutics Australia Pty Ltd

Completed

Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa

Hidradenitis Suppurativa

Australia
Azora Therapeutics Australia Pty Ltd

Active, not recruiting

Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis

Plaque Psoriasis | Nail Psoriasis

Australia
Royan Institute

Completed

Bone Marrow Derived AC 133+ and Mono-Nuclear Cells (MNC) Implantation in Myocardial Infarction (MI) Patient

Myocardial Infarction

Iran, Islamic Republic of
AstraZeneca

Completed

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Non-Insulin-Dependent

United States
Acerta Pharma BV

Active, not recruiting

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United Kingdom, Poland
TD Vaccines A/S
Johns Hopkins University; University of Vermont; SNBL Clinical Pharmacology Center... and other collaborators

Unknown

ACE393-103 Vaccination Challenge Study (ACE393-103VC)

Campylobacter Infection

United States
Royan Institute

Completed

Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction

Myocardial Infarction

Iran, Islamic Republic of
AstraZeneca

Completed

Extension Study for 2993-112

Type 2 Diabetes Mellitus

United States, Canada
AstraZeneca

Completed

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

Diabetes Mellitus, Non-Insulin-Dependent

United States
AstraZeneca

Completed

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Diabetes Mellitus, Type 2

United States
AstraZeneca
Eli Lilly and Company

Completed

Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

Diabetes Mellitus, Type 2

Hungary
AstraZeneca
Eli Lilly and Company

Completed

An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Italy, Korea, Republic of, Hungary, Canada, Australia
AstraZeneca
Eli Lilly and Company

Completed

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
AstraZeneca
Eli Lilly and Company

Completed

Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

Diabetes Mellitus, Type 2

Belgium, United States, Australia, Portugal, Germany, Puerto Rico, Spain, Netherlands, Brazil, Finland, Norway, Poland, Sweden
AstraZeneca
Eli Lilly and Company

Completed

A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Netherlands, Canada
AstraZeneca

Completed

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Non-Insulin-Dependent

United States
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

Type 2 Diabetes Mellitus

United States, Spain, Canada
AstraZeneca
Eli Lilly and Company

Completed

Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

Type 2 Diabetes Mellitus

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

United Kingdom
The Christie NHS Foundation Trust

Terminated

A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy (CD19)

CD19 Positive Non-Hodgkin Lymphoma

United Kingdom
AstraZeneca
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

Diabetes Mellitus

United States
Assistance Publique - Hôpitaux de Paris
Sanofi-Synthelabo

Completed

STRATAGEM: Strategy for Managing Antiplatelet Therapy in the Perioperative Period of Non Coronary Surgery (STRATAGEM)

Thrombosis

France
AstraZeneca
Eli Lilly and Company

Completed

Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

Type 2 Diabetes Mellitus

Italy, Poland, Hungary, Mexico, Greece, Australia
AstraZeneca
Eli Lilly and Company

Completed

The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females

Type 2 Diabetes Mellitus

United Kingdom

3

Subscribe